Dermal Cell News Volume 11.08 | May 05 2025

    0
    42







    2025-05-05 | DCN 11.08


    Dermal Cell News by STEMCELL Technologies
    Vol. 11.08 – 5 May, 2025
    TOP STORY

    Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors

    Researchers investigated the role of nitrosylation, a nitric oxide-induced post-translational modification, in melanoma progression and therapeutic resistance.
    [Cancer Research]

    AbstractPress Release
    Learn strategies and tips for choosing which scientific conferences to attend.
    PUBLICATIONSListed by the impact factor of the journal

    Exosomes from Human Umbilical Cord Mesenchymal Stem Cells Promote the Growth of Human Hair Dermal Papilla Cells

    Investigators found that human umbilical cord mesenchymal stem cell-derived exosomes effectively enhanced the cell growth of human hair dermal papilla cells.
    [PLOS One]

    Full Article

    Rechallenge of Ipilimumab and Nivolumab in Advanced Melanoma Patients after Previous Ipilimumab-Based Therapy

    Data from advanced melanoma patients rechallenged with ipilimumab+nivolumab after previous ipilimumab-containing treatment were retrieved from the nationwide Dutch Melanoma Treatment Registry.
    [British Journal of Cancer]

    Abstract

    ZNF224 Enhances the Oncogenic Function of p21 via p53 and AKT Pathways in Melanoma

    Scientists investigated the molecular mechanisms underlying the oncogenic role of zinc finger protein 224 (ZNF224) in melanoma.
    [FEBS Journal]

    Full Article

    Molecular and Immune Landscape of Melanoma: A Risk Stratification Model for Precision Oncology

    Investigators provided a robust immune-related prognostic model for melanoma. They underscored the value of immune gene expression and T cell infiltration, particularly CD8+ T cells, in predicting patient outcomes.
    [Discover Oncology]

    Full Article

    Investigating the Properties of Truncal Acne: A Common but Often Overlooked Entity

    Researchers investigated the prevalence of truncal acne in patients with mild, moderate, and severe acne and evaluated the characteristics of truncal acne.
    [Journal of Cutaneous Medicine and Surgery]

    Abstract
    Your Online Resource for Cell Visualization. View StainsFile.
    REVIEWS

    The Dynamic Interplay between Melanoma Cells and CAFs: Implications Drug Resistance and Immune Evasion and Possible Therapeutics

    The authors explore different subtypes of cancer-associated fibroblasts, their origins, and how they have evolved in their pro-tumorigenic roles in melanoma.
    [Experimental Cell Research]

    Full Article
    INDUSTRY AND POLICY NEWS

    US FDA Approves ZEVASKYNâ„¢ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

    Abeona Therapeutics, Inc. announced the US FDA has approved ZEVASKYNâ„¢ gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.
    [Abeona Therapeutics, Inc.]

    Press Release
    FEATURED EVENT

    Frontiers in Cancer Immunotherapy

    June 16-17, 2025
    New York, New York, United States & Online

    > See All Events

    JOB OPPORTUNITIES

    PhD Student – Melanoma Drug Resistance

    University of Luxembourg – Esch-sur-Alzette, Luxembourg

    Postdoctoral Training Position – Cell Therapy and Cancer Immunology

    University of Texas Southwestern Medical Center – Dallas, Texas, United States

    Postdoctoral Research Associate – Dominant Dystrophic Epidermolysis Bullosa

    King’s College London – London, England, United Kingdom

    Research Associate / Postdoctoral Position – Regenerative Medicine

    Technische Universität Dresden – Dresden, Germany

    Fellowship – Melanoma & Immuno-Oncology

    BC Cancer – Vancouver Centre – Vancouver, British Columbia, Canada

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2